The extended pharmacokinetic profile allows therapeutic GLP-1 receptor activation throughout the day and night, providing continuous metabolic benefits rather than the transient effects of native GLP-1
The peptide itself is fine
Weight loss with SGLT2 inhibitor therapy has been consistently observed in several studies in T2D, whether patients are taking SGLT2 inhibitors as monotherapy or in combination with additional glucose-lowering therapies (Table 2)
Semaglutide was approved for weight management in 2021, while tirzepatide followed in 2023
Cardiovascular actions of incretin-based therapies
Carla Prado, a nutrition researcher in the Faculty of Agricultural, Life & Environmental Sciences and lead author on the commentary, explains this rate of muscle decline is significantly higher than what is typically observed with calorie-reduced diets or normal aging and could lead to a host of long-term health issues - including decreased immunity, increased risk of infections and poor wound healing
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
